Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Up 1.3% – Here’s Why

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) shares were up 1.3% on Monday . The stock traded as high as $11.94 and last traded at $11.65. Approximately 2,841 shares were traded during trading, a decline of 91% from the average daily volume of 30,110 shares. The stock had previously closed at $11.50.

Finch Therapeutics Group Stock Up 1.3 %

The stock’s fifty day simple moving average is $11.09 and its 200-day simple moving average is $5.08. The company has a market capitalization of $18.71 million, a PE ratio of -1.15 and a beta of 1.34.

Finch Therapeutics Group (NASDAQ:FNCH) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($3.01) earnings per share for the quarter.

Institutional Trading of Finch Therapeutics Group

An institutional investor recently bought a new position in Finch Therapeutics Group stock. Lake Street Advisors Group LLC acquired a new stake in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 21,206 shares of the company’s stock, valued at approximately $56,000. Lake Street Advisors Group LLC owned 1.32% of Finch Therapeutics Group as of its most recent SEC filing. 21.77% of the stock is currently owned by institutional investors.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.